Welcome to our dedicated page for Cencora SEC filings (Ticker: COR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Cencora, Inc. (NYSE: COR) SEC filings page on Stock Titan provides centralized access to the company’s regulatory disclosures filed with the U.S. Securities and Exchange Commission. As a large pharmaceutical solutions and distribution organization, Cencora uses its SEC reports to present detailed information about its financial performance, capital structure, governance, and significant transactions.
Investors can review Form 10-K annual reports and Form 10-Q quarterly reports to understand Cencora’s revenue composition, segment performance for U.S. Healthcare Solutions and International Healthcare Solutions, and the impact of acquisitions such as Retina Consultants of America. These filings also describe non-GAAP measures like adjusted operating income and adjusted diluted earnings per share, along with reconciliations to GAAP metrics.
Cencora’s Form 8-K current reports offer timely updates on material events, including amendments to credit facilities, changes to its receivables securitization program, issuance and listing of senior notes, revisions to its reporting structure, and agreements to acquire additional equity interests in OneOncology. Other 8-Ks disclose governance developments, such as board appointments and leadership changes, as well as information about legal settlements and derivative actions.
Through Stock Titan, users can also track registered debt securities like Cencora’s 2.875% Senior Notes due 2028 (COR28) and 3.625% Senior Notes due 2032 (COR32), which are listed alongside the common stock. Where available, insider transaction reports on Forms 3, 4, and 5 can help users monitor equity ownership changes by directors and officers.
AI-powered tools on the platform summarize lengthy Cencora filings, highlight key changes from prior periods, and surface important disclosures about liquidity, financing arrangements, segment realignments, and legal matters. This helps readers quickly interpret complex documents and focus on the sections most relevant to their analysis of COR.
Robert P. Mauch reported proposed and completed sales of Common stock.
The filing shows proposed sale of 3,762 shares via an option-related transaction dated 02/20/2026 (method: cash). It also lists completed sales: 5,096 shares on 12/18/2025$1,750,221.20, 5,096 shares on 01/20/2026$1,807,704.08, and 1,333 shares on 02/18/2026$479,160.18.
COR reported proposed sales of common stock by a holder under Rule 144. The filing lists three sales by Robert Mauch: 11/18/2025 5,096 shares for $1,868,397.44; 12/18/2025 5,096 shares for $1,750,221.20; and 01/20/2026 5,096 shares for $1,807,704.08.
The excerpt also records restricted stock vesting entries dated 11/09/2024 (587 shares) and 11/10/2024 (746 shares) attributed to issuer compensation.
Cencora has agreed to merge its animal health business, MWI Animal Health, with Covetrus, valuing MWI at an enterprise value of $3.5 billion. At closing, Cencora will receive $1.25 billion in cash plus equity in the combined parent, including $800 million of perpetual preferred units and $1.45 billion of common units.
After the merger closes and regulatory and other customary conditions are met, Cencora expects to own about 34.3% of the combined CVET TopCo, LP as a non‑controlling shareholder. Cencora notes that its fiscal 2026 guidance does not assume the transaction will close within its 2026 fiscal year.
Cencora, Inc. completed a public offering of $3.0 billion of unsecured senior notes across five tranches, with coupons ranging from 3.950% to 5.650% and maturities from 2029 to 2056. The notes are issued under a long-standing indenture with U.S. Bank Trust Company as trustee and include standard covenants on liens, sale-leasebacks, and mergers, plus customary events of default that can accelerate repayment.
Cencora intends to use the net proceeds to repay amounts outstanding under its 364-Day Term Credit Agreement, which helped fund its acquisition of OneOncology, and to use any remaining funds for general corporate purposes. This transaction replaces short-term acquisition financing with longer-term fixed-rate debt.
Cencora, Inc. is issuing $3.0 billion of unsecured senior notes in five tranches maturing between 2029 and 2056, with fixed coupons ranging from 3.950% to 5.650%. Interest will be paid semi‑annually, and the notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to subsidiary liabilities.
Cencora expects net proceeds of about $2.98 billion, which it intends to use to repay in full its $3.0 billion 364‑Day Term Loan Facility used to help fund the approximately $4.6 billion acquisition of OneOncology, with any remaining funds for general corporate purposes.
The notes are redeemable at Cencora’s option (including make‑whole and par call structures) and must be offered for repurchase at 101% of principal plus accrued interest if a defined Change of Control Triggering Event occurs. The securities will be issued in book‑entry form and are not expected to be listed on any exchange.
Cencora, Inc. has priced a multi-tranche senior notes offering totaling $3.0 billion, issuing five series of senior unsecured notes maturing between 2029 and 2056 with coupons ranging from 3.950% to 5.650% in an underwritten registered public offering.
Cencora expects to receive approximately $2.98 billion in net proceeds and plans to use the funds primarily to repay borrowings under its $3.0 billion 364-Day Term Loan Facility used to help finance the OneOncology acquisition, with any remaining proceeds earmarked for general corporate purposes.
Cencora, Inc. plans a multi‑tranche unsecured senior notes offering, with each series paying fixed interest semi‑annually and maturing on different future dates. The notes rank equally with Cencora’s other unsecured, unsubordinated debt and are structurally subordinated to liabilities at subsidiaries.
Cencora intends to use the net proceeds to repay in full borrowings under its $3.0 billion 364‑Day Term Loan Facility, which helped fund the approximately $4.6 billion acquisition of OneOncology, and, if any funds remain, for general corporate purposes. A change of control triggering event requires Cencora to offer to repurchase the notes at 101% of principal plus accrued interest, and the notes are redeemable at Cencora’s option subject to make‑whole and par call terms.
Cencora, Inc. filed an 8-K to revise how it presents past financial results, aligning its 2025 Form 10-K disclosures with a new segment structure: U.S. Healthcare Solutions, International Healthcare Solutions, and Other. The change only recasts segment information and does not amend audited financial statements.
Under this structure, fiscal 2025 revenue was $321.3 billion, up 9.3% from 2024, led by U.S. Healthcare Solutions revenue of $285.0 billion, up 9.8%, driven by higher specialty volumes and an additional $7.7 billion of GLP‑1 diabetes and weight‑loss products. Gross profit rose 15.8% to $11.48 billion, and operating income increased 20.8% to $2.63 billion.
Cencora closed the $4.04 billion cash acquisition of Retina Consultants of America in January 2025, plus related contingent consideration, strengthening its retina specialty platform. The company also recorded a $723.9 million goodwill impairment for its PharmaLex reporting unit and reported a 2025 effective tax rate of 30.6%.
Cencora, Inc. reports higher results for the quarter ended December 31, 2025, with revenue of $85.9 billion, up 5.5% year over year, and net income of $566.1 million. Diluted earnings per share were $2.87, compared with $2.50 a year earlier.
Growth was driven mainly by the U.S. Healthcare Solutions segment, where revenue rose 5.0% and gross profit increased 29.5%, helped by the January 2025 acquisition of Retina Consultants of America and strong specialty and GLP‑1 product sales. International Healthcare Solutions revenue grew 9.6%, led by European distribution.
Operating income rose 7.7% to $760.4 million, despite a $249.5 million impairment tied to the U.S. Consulting Services business held for sale. Results benefited from an $86.8 million litigation credit from a derivative lawsuit settlement and a higher LIFO credit of $77.6 million. Cash used in operating activities was $2.3 billion, largely from higher inventories and receivables, while total debt was $7.9 billion. The company also highlights a $4.6 billion cash acquisition of OneOncology completed in February 2026, funded with new debt.
Cencora, Inc. reported quarterly results for the fiscal quarter ended December 31, 2025 via a news release furnished as an exhibit, and is holding a conference call and webcast to discuss these results and related matters.
The company also acquired the majority of the outstanding equity interests it did not previously own in OneOncology, a national oncology-focused physician platform, for total cash consideration of approximately $4.6 billion, funded through new debt financing. OneOncology’s affiliated practices and management retained a minority interest, and OneOncology’s future operating results will be included in Cencora’s U.S. Healthcare Solutions segment.